Novan to Provide Corporate Update at its 2023 Annual Meeting of Stockholders
DURHAM, N.C., June 05, 2023 (GLOBE NEWSWIRE) — Novan, Inc. (“the Company” or “Novan”) (Nasdaq:…
Month: June 2023
Shanghai Escugen Biotechnology Co., Ltd., a partner of Levena Biopharma, a Sorrento Company, releases positive results from a first-in-human study of ESG401, a TROP2 Antibody Drug Conjugate in patients with locally advanced/metastatic solid tumors at the ASCO 2023 Meeting
Figure 1 Sorrento Therapeutics, Inc. Figure 2 Sorrento Therapeutics, Inc. Figure 3 Sorrento Therapeutics, Inc….
Shanghai Escugen Biotechnology Co., Ltd., a partner of Levena Biopharma, a Sorrento Company, releases positive results from a first-in-human study of ESG401, a TROP2 Antibody Drug Conjugate in patients with locally advanced/metastatic solid tumors at the ASCO 2023 Meeting
Figure 1 Sorrento Therapeutics, Inc. Figure 2 Sorrento Therapeutics, Inc. Figure 3 Sorrento Therapeutics, Inc….
Lucy Scientific Discovery Announces Proposal to Acquire Pasithea Therapeutics Corp.
VANCOUVER, British Columbia, June 05, 2023 (GLOBE NEWSWIRE) — Lucy Scientific Discovery Inc. (“Lucy” or…
Lucy Scientific Discovery Announces Proposal to Acquire Pasithea Therapeutics Corp.
VANCOUVER, British Columbia, June 05, 2023 (GLOBE NEWSWIRE) — Lucy Scientific Discovery Inc. (“Lucy” or…
T2 Biosystems Announces Submission for FDA Breakthrough Device Designation for Candida Auris Diagnostic Test
Company plans to add multidrug-resistant Candida auris detection to its FDA-cleared T2Candida Panel LEXINGTON, Mass.,…
T2 Biosystems Announces Submission for FDA Breakthrough Device Designation for Candida Auris Diagnostic Test
Company plans to add multidrug-resistant Candida auris detection to its FDA-cleared T2Candida Panel LEXINGTON, Mass.,…
Surrozen Publishes Study in Nature Communications Demonstrating the Promise of a Fzd4 Wnt Antibody in Treating Ischemic Stroke
In a preclinical model of ischemic stroke, systemic delivery of a selective Fzd4 Wnt antibody…
Surrozen Publishes Study in Nature Communications Demonstrating the Promise of a Fzd4 Wnt Antibody in Treating Ischemic Stroke
In a preclinical model of ischemic stroke, systemic delivery of a selective Fzd4 Wnt antibody…
Tarsus to Present at the Jefferies Global Healthcare Conference
IRVINE, Calif., June 05, 2023 (GLOBE NEWSWIRE) — Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission…
Tarsus to Present at the Jefferies Global Healthcare Conference
IRVINE, Calif., June 05, 2023 (GLOBE NEWSWIRE) — Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission…
Ambrx Appoints Jared Kelly as General Counsel
SAN DIEGO, June 05, 2023 (GLOBE NEWSWIRE) — Ambrx Biopharma Inc., or Ambrx (NASDAQ: AMAM),…
Ambrx Appoints Jared Kelly as General Counsel
SAN DIEGO, June 05, 2023 (GLOBE NEWSWIRE) — Ambrx Biopharma Inc., or Ambrx (NASDAQ: AMAM),…
Poster Highlighting Qualigen Therapeutics’ Pan-RAS Inhibitor Platform Presented at American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
Qualigen Therapeutics, Inc. Co-operation between RAS-F series and AMG-510 and MRTX1133 Preclinical Data Show Potential…
Poster Highlighting Qualigen Therapeutics’ Pan-RAS Inhibitor Platform Presented at American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
Qualigen Therapeutics, Inc. Co-operation between RAS-F series and AMG-510 and MRTX1133 Preclinical Data Show Potential…
Morphogenesis, Inc. and CohBar, Inc. Announce Positive Results from Phase 1b Trial of IFx-Hu2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC)
IFx-Hu2.0 demonstrated to have a promising safety profile at all 3 dose schedules tested 5…
Morphogenesis, Inc. and CohBar, Inc. Announce Positive Results from Phase 1b Trial of IFx-Hu2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC)
IFx-Hu2.0 demonstrated to have a promising safety profile at all 3 dose schedules tested 5…
NexImmune Presents Initial Positive Data from the NEXI-001 Phase 1 Trial for Relapsed/Refractory Post Allo-HSCT AML at the American Society of Clinical Oncology 2023 Annual Meeting
– Trial includes high risk AML patients that have relapsed post allo-HSCT and are refractory…
NexImmune Presents Initial Positive Data from the NEXI-001 Phase 1 Trial for Relapsed/Refractory Post Allo-HSCT AML at the American Society of Clinical Oncology 2023 Annual Meeting
– Trial includes high risk AML patients that have relapsed post allo-HSCT and are refractory…
Atreca Presents Data from Ongoing Phase 1b Study of ATRC-101 in Patients with Select Advanced Solid Tumors during Oral Abstract Session at the ASCO 2023 Annual Meeting
Clinical activity observed in multiple tumor types; longer progression-free survival observed in patients with high…